Empagliflozin verbessert kardiovaskuläre Prognose

Jardiance, INN-Empagliflozin

Ein Expertensystem verbessert die Qualität der medizinischen Praxis

The knowledge base fort he practice of medicine is growing exponentially. To digest the available new information, a practitioner had to read almost all of his time and would not be able to treat patients. Since the economic burden is pressing doctors to see more patients in a shortage of time, the quality of the so-called evidence based medicine in practical medicine is declining. Additionally...

Prognose freier Rechenkapazitäten zur besseren Nutzung von Grid-Ressourcen

Vor allem in der Forschung und in den Entwicklungsabteilungen von Unternehmen gibt es eine Vielzahl von Problemen, welche nur mit Programmen zu lösen sind, für deren Ausführung die zur Verfügung stehende Rechenleistung kaum groß genug sein kann. Gleichzeitig ist zu beobachten, dass ein großer Teil der mit der installierten Rechentechnik vorhandenen Rechenkapazität nicht ausgenutzt wird. Dies gi...

Empagliflozin: Novel antidiabetes and pro-cardiac drug

Empagliflozin has been shown to improve glycaemic control and reduce CV mortality along with salutary effects on renal outcomes as compared to placebo in a recently conducted EMPA-REG OUTCOME trial in a large number of patients.[1,2] In this study, more than 7000 patients were randomly assigned to receive empagliflozin in the dose of 10 mg or 25 mg or placebo once daily. Patients were followed ...

Empagliflozin and the Prevention of Heart€Failure

SEE PAGE 347 H eart failure develops in more than 1 in 5 patients with diabetes mellitus (DM) older than 65 years of age and augers an extremely poor prognosis, with a median survival of approximately 4 years. The landmark EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) showed that empagliflozin significantly reduced the primary composite...